What was tested

He and colleagues asked whether Notoginsenoside R1 (NGR1), a saponin from Panax notoginseng, can drive human dental pulp stem cells (hDPSCs) toward odontogenic differentiation and improve reparative dentin after direct pulp capping. The work has three parts: in vitro hDPSC assays, an adult dog direct pulp capping model, and RNA sequencing of NGR1-treated hDPSCs followed by pathway and protein-protein interaction analyses (He et al. 2026, abstract, Methods). It is a preclinical study, not a human trial.

In vitro: proliferation, migration, and mineralization

The authors isolated and characterized hDPSCs, then treated them with NGR1 at 0, 50, 100, or 200 micrograms per milliliter. They measured proliferation by CCK-8, migration by Transwell, and odontogenic differentiation by alkaline phosphatase (ALP) and Alizarin Red S staining. Reverse-transcription PCR tracked ALP and dentin sialophosphoprotein (DSPP) mRNA.

Across these assays, NGR1 increased hDPSC proliferation, migration, and signs of odontogenic differentiation. Both the 100 and 200 micrograms per milliliter groups enhanced mineralized nodule formation. ALP and DSPP mRNA were significantly upregulated in NGR1-treated groups. The authors concluded that 100 micrograms per milliliter offers the best balance between proliferation and pro-differentiation effects (He et al. 2026, abstract, Results).

In vivo: adult dog direct pulp capping

The animal arm used adult dogs with mechanically exposed pulp. The experimental group received a 100 micrograms per milliliter NGR1 rinse before capping; the control group did not. Dogs were euthanized at 1, 4, 8, and 12 weeks, and samples were examined by micro-CT and hematoxylin and eosin staining.

Both groups formed continuous, uniform, and thickened reparative dentin over time, and both showed dentin bridges at 4, 8, and 12 weeks. The difference was organizational: the NGR1-treated reparative dentin appeared to contain more numerous, regularly arranged dentinal tubules and a more compact architecture, while the control dentin looked less organized (He et al. 2026, abstract, Results). So NGR1 did not switch reparative dentin on or off; it improved the microstructural quality of dentin that formed anyway.

Transcriptomic hints, not a mechanism

RNA sequencing of hDPSCs treated with 100 micrograms per milliliter NGR1 identified 50 upregulated differentially expressed genes. One dentin-related gene highlighted by the authors is S100A9. The enriched gene sets included complement and coagulation cascades, cytokine-cytokine receptor interaction, Staphylococcus aureus infection, and tuberculosis pathways. Protein-protein interaction analysis flagged SPRR1A, SPRR1B, and SPRR3 as potential hub genes, and RT-PCR and immunohistochemistry reportedly matched the sequencing trends (He et al. 2026, abstract, Results).

Those pathway labels are broad immune and stress-response signatures. The authors frame them as a basis for future mechanistic studies, which is the right weight: from this experiment they cannot show that any of those pathways causes the dentin effect. They are correlates of NGR1 exposure in cultured cells.

What it does not show

This is not a person treated, a regenerated tooth, or a clinical trial. The in vivo result is in adult dogs, with one NGR1 concentration and no reported dose response. The control group also formed reparative dentin and dentin bridges, so the benefit is in dentin quality, not in proving that NGR1 is required for repair. We could not read the publisher full text; only the Europe PMC structured abstract was available, so we cite no figure numbers, sample sizes, exact p-values, or histology beyond what the abstract reports.

Where we differ from the coverage

We found no lay or popular coverage of this paper to differ from. The closest risk of overstatement is in the abstract’s own closing: the authors call NGR1 a candidate for expanding direct pulp capping. That is a reason for further preclinical study, not evidence that a therapy exists.

Where this sits

For the pulp and dentin repair program, NGR1 joins a growing list of small-molecule and natural-product candidates that show dentin-marker upregulation in human pulp cells and some histological repair in animal pulp injury models. It does not change the program’s tier: the strongest human evidence in this route remains the randomized 26-patient autologous pulp stem cell graft trial. The honest next steps are a dose response in vivo, an independent replication, and a causal test of whether the transcriptomic signatures have anything to do with the dentin phenotype. The current field assessment is at /field/.

Provenance: grounded in the Europe PMC structured abstract and metadata for DOI 10.1016/j.tice.2026.103858 (PMID 42612582). The publisher full text was not open access and was not read, so no figures, sample sizes, or statistics beyond the abstract are claimed. Sourcing standard at /method/.